The effect of eplerenone vs. placebo on cardiovascular mortality
Monday, August 29, 2011 - 09:30
in Health & Medicine
Today results from a new sub-analysis of the EMPHASIS-HF study showed significant reductions in death and hospitalization for five pre-defined high-risk patient sub-groups with chronic heart failure (CHF) and mild symptoms treated with eplerenone in addition to standard therapy versus those treated with placebo and standard therapy.